Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
-
Promising prostate cancer combo study halted early
Disease control TerminatedThis study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all …
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New inhaler for COPD shows promise in early trial
Disease control TerminatedThis study tested an experimental inhaled drug called HRG2005 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The goal was to see if it improves lung function compared to a standard treatment. About 82 participants were enrolled, but the study was …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Lung cancer drug cocktail trial ends early – what we know
Disease control TerminatedThis phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see i…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC